|
Demographic characteristics
|
|
Age, years
|
67.2 ± 7.8
|
69.4 ± 7.8
|
0.274
|
|
Male sex, n (%)
|
19 (63.3)
|
26 (89.7)
|
0.018
|
|
Cardiovascular risk factors
|
|
Hyperlipidaemia, n (%)
|
30 (100)
|
29 (100)
|
–
|
|
Hypertension, n (%)
|
29 (96.7)
|
29 (100)
|
–
|
|
Diabetes, n (%)
|
8 (26.7)
|
8 (27.6)
|
0.937
|
|
Peripheral vascular disease, n (%)
|
10 (33.3)
|
12 (41.4)
|
0.523
|
|
Current smoker, n (%)
|
1 (3.3)
|
4 (13.8)
|
0.195
|
|
Positive family history for CVD, n (%)
|
10 (33.3)
|
19 (5.5)
|
0.013
|
|
Medical history
|
|
Previous myocardial infarction, n (%)
|
15 (50.0)
|
23 (79.3)
|
0.019
|
|
Previous percutaneous intervention, n (%)
|
16 (53.3)
|
15 (51.7)
|
0.902
|
|
Previous CABG, n (%)
|
20 (66.7)
|
18 (62.1)
|
0.712
|
|
No revascularization, n (%)
|
7 (23.3)
|
7 (24.1)
|
0.936
|
|
Three-vessel disease, n (%)
|
24 (80.0)
|
22 (75.9)
|
0.161
|
|
Two-vessel disease, n (%)
|
5 (16.7)
|
2 (6.9)
|
|
Clinical parameters
|
|
Body mass index, kg/m2
|
30.0 ± 4.3
|
30.3 ± 3.8
|
0.755
|
|
Angina episodes/week, median (25%;75%)
|
5.5 (3.3; 14.8)
|
7 (3.8; 15)
|
0.500
|
|
Nitroglycerine consumption (times/week), median (25%;75%)
|
2 (1; 2)
|
2 (0; 5)
|
0.250
|
|
Left ventricular ejection fraction (echocardiographic), %
|
54.4 ± 9.5
|
56.0 ± 7.2
|
0.366
|
|
Systolic blood pressure, mmHg
|
124.7 ± 20.9
|
128.1 ± 22.1
|
0.845
|
|
Diastolic blood pressure, mmHg
|
81.1 ± 11.3
|
77.0 ± 11.2
|
0.341
|
|
Angina CCS class
|
|
II, n (%)
|
8 (26.7)
|
9 (31.0)
|
0.711
|
|
III, n (%)
|
22 (73.3)
|
20 (69.0)
|
|
Medical treatment
|
|
ACE inhibitors / ARB, n (%)
|
30 (100)
|
29 (100)
|
–
|
|
Beta-blocker, n (%)
|
28 (93.1)
|
27 (93.1)
|
1
|
|
Long acting nitrates, n (%)
|
19 (63.3)
|
15 (51.7)
|
0.367
|
|
Calcium channel blocker, n (%)
|
16 (51.3)
|
15 (51.7)
|
0.902
|
|
Trimetazidine, n (%)
|
20 (66.7)
|
15 (51.7)
|
0.243
|
|
Statins, n (%)
|
30 (100)
|
29 (100)
|
–
|
|
Mean dose of atorvastatin, mg
|
36.2 ± 11.8a
|
40.3 ± 17.0
|
0.286
|
|
Antiplatelets, n (%)
|
30 (100)
|
29 (100)
|
–
|
|
Dual-antiplatelet therapy, n (%)
|
4 (13.3)
|
11 (37.9)
|
0.031
|
|
Oral anti-diabetics, n (%)
|
4 (13.3)
|
7 (24.1)
|
0.287
|
|
ECG Exercise test
|
|
Exercise duration, sec
|
350.1 ± 133.1
|
370.4 ± 131.0
|
0.558
|
